首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   175197篇
  免费   967篇
  国内免费   2篇
耳鼻咽喉   1141篇
儿科学   6626篇
妇产科学   3021篇
基础医学   16440篇
口腔科学   1553篇
临床医学   12325篇
内科学   30641篇
皮肤病学   667篇
神经病学   16418篇
特种医学   8939篇
外科学   28792篇
综合类   2317篇
预防医学   18118篇
眼科学   2763篇
药学   9459篇
中国医学   642篇
肿瘤学   16304篇
  2022年   33篇
  2021年   42篇
  2020年   40篇
  2019年   59篇
  2018年   21957篇
  2017年   17387篇
  2016年   19535篇
  2015年   915篇
  2014年   812篇
  2013年   763篇
  2012年   6948篇
  2011年   20980篇
  2010年   18796篇
  2009年   11494篇
  2008年   19449篇
  2007年   21648篇
  2006年   475篇
  2005年   2102篇
  2004年   3299篇
  2003年   4284篇
  2002年   2431篇
  2001年   266篇
  2000年   415篇
  1999年   162篇
  1998年   197篇
  1997年   201篇
  1996年   88篇
  1995年   99篇
  1994年   97篇
  1993年   56篇
  1992年   39篇
  1991年   85篇
  1990年   126篇
  1989年   80篇
  1988年   56篇
  1987年   39篇
  1986年   27篇
  1985年   37篇
  1984年   26篇
  1983年   26篇
  1980年   43篇
  1974年   26篇
  1970年   27篇
  1969年   26篇
  1968年   26篇
  1938年   60篇
  1937年   25篇
  1934年   30篇
  1932年   56篇
  1930年   47篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Single-agent chemotherapy of metastatic breast cancer is the treatment of choice in patients with slow tumor progression and asymptomatic disease. In this patient group, the choice of drugs is based more on good tolerability than on efficacy. By contrast, symptomatic or rapidly progressing disease requires the use of highly active regimens where more weight is put on reliable antitumor activity. While anthraycline-based combination regimens have set the standard of effective treatment, the addition of docetaxel (and to a lesser extent paclitaxel) has improved tumor response, but failed to induce a consistent prolongation of survival. Based on retrospective analyses, it is hypothesised that the combined use of anthracyclines and taxanes in first-line therapy may be most beneficial in defined subgroups: after adjuvant chemotherapy, in patients with HER-2 gene amplification, possibly also in patients with rapidly progressing visceral disease.  相似文献   
102.
103.
104.
105.
106.
Antegrade interlocking nailing of humeral shaft fractures   总被引:5,自引:0,他引:5  
The results of 39 humeral shaft fractures (37 patients) treated with antegrade locked nailing using a Russell–Taylor nail were reviewed. There were 30 acute fractures, 6 fractures malaligned in a hanging cast or brace, and 3 pathological fractures. Patient age ranged from 26 to 80 years (average, 59.7 years) and average follow-up was 25.7 months (range, 6–48 months). Fracture union was achieved in 92.3% of our cases, while shoulder function was excellent or good in 87.2% of cases. Antegrade locked nailing offers a dependable solution for the treatment of humeral shaft fractures, especially in polytrauma patients and cases of segmental or pathological fractures. Far less satisfactory results were obtained in comminuted fractures of the proximal third in the humerus, especially in osteoporotic patients, and we therefore advocate caution with the use of intramedullary nailing in this type of fracture. Certain technical aspects such as avoiding nailing the fracture in distraction, properly countersinking the tip of the nail, and achieving adequate fixation stability have been found to be of paramount importance to reduce the incidence of delayed union/non-union rate and to obtain better functional results from the shoulder joint.  相似文献   
107.
108.
Background: Studies suggest that the period following completion of treatment can be distressing for cancer patients. One potentially important predictor of distress is physical symptoms/side effects during treatment.Purpose: A longitudinal, observational design was used to examine whether the number of physical symptoms/side effects experienced during treatment was a correlate of cancer-related distress and general distress 4 months after treatment completion, as measured by the Impact of Events Scale and the Mental Health subscale of the Short Form-36, respectively.Methods: Participants were 151 women who had completed chemotherapy and/or radiotherapy for ductal carcinoma in situ or stage 1 or 2 breast cancer. Hierarchical multiple regression was conducted with relevant sociodemographic, clinical, and psychiatric variables entered as controls.Results: Greater physical symptoms/side effects predicted greater total cancer-related distress, intrusive thoughts, and general distress. Physical symptoms/side effects did not significantly predict avoidance. Follow-up analyses indicated that the relationship between physical symptoms/side effects and general distress was mediated by both total cancer-related distress and intrusive thoughts.Conclusions: These results suggest that patients who experience greater physical symptoms/side effects during treatment are at greater risk for later cancer-related distress and, in turn, general distress. Future research should evaluate whether early intervention with these patients is effective in preventing or reducing distress in the posttreatment period. This work was supported by a grant from the National Cancer Institute (5R01 CA082822).  相似文献   
109.
Summary: To develop a method for identification of differential gene expression between different cell populations, several convenient techniques of molecular biology, including subtractive hybridization, suppression PCR, T/A cloning and sequencing, were used to identify genes expressed differentially in CD45^- and CD45^- cells isolated from U266 cell line of multiple myeloma. Our results showed that the levels of abundant genes scale down 20 times through subtractive hybridization.Plasmid DNA from CD45^- cell clones was hybridized with forward or backward cDNA probes synthesized from CD45^- and CD45 cells, respectively. A few of differentially expressed genes reconfirmed by RT-PCR were identified from 500 expressed clones of CD45^- cells. It is concluded that a strategy for gene expression identification developed from conventional molecular biological methods can be used in different laboratories.  相似文献   
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号